Patents by Inventor Vineet Pande

Vineet Pande has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL SPIROBICYCLIC ANALOGUES
    Publication number: 20200369707
    Abstract: The present invention relates to novel spirobicyclic analogues of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as PRMT5 inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
    Type: Application
    Filed: December 6, 2018
    Publication date: November 26, 2020
    Inventors: Jonas VERHOEVEN, Guido Alfons F. VERNIEST, Johannes Wilhelmus John F. THURING, Tongfei WU, Vineet PANDE, Lieven MEERPOEL, Dirk BREHMER, Weimei SUN, Scott E. DENMARK
  • NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS
    Publication number: 20200360416
    Abstract: Embodiments of the present invention relate to 6-6 bicyclic aromatic ring substituted nucleoside analogues, including, for example, the following compound: Embodiments of the present invention also relate to uses of the disclosed compounds for the inhibition of protein arginine methyltransferase 5 (PRMT5).
    Type: Application
    Filed: March 20, 2020
    Publication date: November 19, 2020
    Inventors: Tongfei Wu, Dirk Brehmer, Lijs Beke, An Boeckx, Gaston Stanislas Marcella Diels, Ronaldus Arnodus Hendrika Joseph Gilissen, Edward Charles Lawson, Vineet Pande, Marcus Cornelis Bernardus Catharina Paradé, Wim Bert Griet Schepens, Johannes Wilhelmus John F. Thuring, Marcel Viellevoye, Weimei Sun, Lieven Meerpoel
  • Azepane Inhibitors Of Menin-MLL Interaction
    Publication number: 20200339594
    Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to azepane compounds, pharmaceutical composition comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, myelodysplastic syndrome (MDS) and diabetes.
    Type: Application
    Filed: July 17, 2020
    Publication date: October 29, 2020
    Inventors: Patrick Rene Angibaud, Vineet Pande, Barbara Herkert, Daniel Jason Krosky, Olivier Alexis Georges Querolle, Aaron Nathaniel Patrick, Isabelle Noelle Constance Pilatte
  • NOVEL SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS
    Publication number: 20200289539
    Abstract: The present invention relates novel substituted nucleoside analogues of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as PRMT5 inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
    Type: Application
    Filed: February 24, 2017
    Publication date: September 17, 2020
    Inventors: Didier Jean-Claude BERTHELOT, Dirk BREHMER, Lijs BEKE, An BOECKX, Gaston Stanislas Marcella DIELS, Ronaldus Arnodus Hendrika Joseph GILISSEN, Edward Charles LAWSON, Vineet PANDE, Marcus Cornells Bernardus Catbarina PARADE, Wim Bert Griet SCHEPENS, Brian Christopher SHOOK, Johannes Wilhelmus John F. THURING, Marcel VIELLEVOYE, Weimei SUN, Tongfei WU, Lieven MEERPOEL
  • Azepane inhibitors of menin-MLL interaction
    Patent number: 10745409
    Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to azepane compounds, pharmaceutical composition comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, myelodysplastic syndrome (MDS) and diabetes.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: August 18, 2020
    Assignee: Janssen Pharmaceutica NV
    Inventors: Patrick René Angibaud, Vineet Pande, Barbara Herkert, Daniel Jason Krosky, Olivier Alexis Georges Querolle, Aaron Nathaniel Patrick, Isabelle Noëlle Constance Pilatte
  • FUSED BICYCLIC INHIBITORS OF MENIN-MLL INTERACTION
    Publication number: 20200172556
    Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to fused bicyclic compounds, pharmaceutical composition comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, myelodysplastic syndrome (MDS) and diabetes.
    Type: Application
    Filed: February 13, 2020
    Publication date: June 4, 2020
    Inventors: Patrick Rene ANGIBAUD, Vineet PANDE, Barbara HERKERT, Daniel Jason KROSKY, Olivier Alexis Georges QUEROLLE, Aaron Nathaniel PATRICK
  • 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors
    Patent number: 10653711
    Abstract: Embodiments of the present invention relate to 6-6 bicyclic aromatic ring substituted nucleoside analogues, including, for example, the following compound: Embodiments of the present invention also relate to uses of the disclosed compounds for the inhibition of protein arginine methyltransferase 5 (PRMT5).
    Type: Grant
    Filed: August 25, 2016
    Date of Patent: May 19, 2020
    Assignee: Janssen Pharmaceutica NV
    Inventors: Tongfei Wu, Dirk Brehmer, Lijs Beke, An Boeckx, Gaston Stanislas Marcella Diels, Ronaldus Arnodus Hendrika Joseph Gilissen, Edward Charles Lawson, Vineet Pande, Marcus Cornelis Bernardus Catharina Paradé, Wim Bert Griet Schepens, Johannes Wilhelmus John F. Thuring, Marcel Viellevoye, Weimei Sun, Lieven Meerpoel
  • Substituted Thiohydantoin Derivatives As Androgen Receptor Antagonists
    Publication number: 20200109150
    Abstract: Disclosed are compounds, compositions and methods for treating of disorders that are affected by the antagonism of one or more androgen receptor types. Such compounds are represented by Formula (I) as follows: wherein R1 and G are defined herein.
    Type: Application
    Filed: November 8, 2019
    Publication date: April 9, 2020
    Inventors: Gilles Bignan, Peter J. Connolly, Ian Hickson, Lieven Meerpoel, Vineet Pande, Zhuming Zhang, Jonathan Branch, Christian Rocaboy, Luis B. Trabalón Escolar
  • Fused bicyclic inhibitors of menin-MLL interaction
    Patent number: 10611778
    Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to fused bicyclic compounds, pharmaceutical composition comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, myelodysplastic syndrome (MDS) and diabetes.
    Type: Grant
    Filed: September 13, 2017
    Date of Patent: April 7, 2020
    Assignee: Janssen Pharmaceutica NV
    Inventors: Patrick Rene Angibaud, Vineet Pande, Barbara Herkert, Daniel Jason Krosky, Olivier Alexis Georges Querolle, Aaron Nathaniel Patrick
  • Substituted thiohydantoin derivatives as androgen receptor antagonists
    Patent number: 10501469
    Abstract: Disclosed are compounds, compositions and methods for treating of disorders that are affected by the antagonism of one or more androgen receptor types. Such compounds are represented by Formula (I) as follows: wherein R1 and G are defined herein.
    Type: Grant
    Filed: June 19, 2018
    Date of Patent: December 10, 2019
    Assignee: Janssen Pharmaceutica NV
    Inventors: Gilles Bignan, Peter J. Connolly, Ian Hickson, Lieven Meerpoel, Vineet Pande, Zhuming Zhang, Jonathan Branch, Christian Rocaboy, Luis B. Trabalón Escolar
  • SUBSTITUTED HYDANTOIN AND THIOHYDANTOIN DERIVATIVES AS ANDROGEN RECEPTOR ANTAGONISTS
    Publication number: 20190337924
    Abstract: Disclosed are compounds, compositions and methods for treating of disorders that are affected by the antagonism of one or more androgen receptor types. Such compounds are represented by Formula (I) as follows: wherein R1a, R2a, R2b, Z, X, Y, and G are defined herein.
    Type: Application
    Filed: June 13, 2019
    Publication date: November 7, 2019
    Inventors: Gilles Bignan, Peter J Connolly, Jan Hickson, Lieven Meerpoel, Vineet Pande, Zhuming Zhang, Jonathan Branch, Christian Rocaboy, Luis B Trabalón Escolar
  • SUBSTITUTED HYDANTOIN AND THIOHYDANTOIN DERIVATIVES AS ANDROGEN RECEPTOR ANTAGONISTS
    Publication number: 20190330190
    Abstract: Disclosed are compounds, compositions and methods for treating of disorders that are affected by the antagonism of one or more androgen receptor types. Such compounds are represented by Formula (I) as follows: wherein R1, R2a, R2b, Z, X, Y, and G are defined herein.
    Type: Application
    Filed: June 13, 2019
    Publication date: October 31, 2019
    Inventors: Gilles Bignan, Peter J. Connolly, Ian Hickson, Lieven Meerpoel, Vineet Pande, Zhuming Zhang, Jonathan Branch, Christian Rocaboy, Luis B. Trabalón Escolar
  • AZEPANE INHIBITORS OF MENIN-MLL INTERACTION
    Publication number: 20190322685
    Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to azepane compounds, pharmaceutical composition comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, myelodysplastic syndrome (MDS) and diabetes.
    Type: Application
    Filed: December 14, 2017
    Publication date: October 24, 2019
    Inventors: Patrick René ANGIBAUD, Vineet PANDE, Barbara HERKERT, Daniel Jason KROSKY, Olivier Alexis Georges QUEROLLE, Aaron Nathaniel PATRICK, Isabelle Noëlle Constance PILATTE
  • NOVEL MONOCYCLIC AND BICYCLIC RING SYSTEM SUBSTITUTED CARBANUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS
    Publication number: 20190263833
    Abstract: The present invention relates to novel novel monocyclic and bicyclic ring system substituted carbanucleoside analogues of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as PRMT5 inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
    Type: Application
    Filed: October 2, 2017
    Publication date: August 29, 2019
    Inventors: Tongfei WU, Dirk BREHMER, Lijs BEKE, An BOECKX, Gaston Stanislas Marcella DIELS, Edward Charles LAWSON, Lieven MEERPOEL, Vineet PANDE, Marcus Cornelis Bernardus Catharina PARADÉ, Wim Bert Griet SCHEPENS, Weimei SUN, Johannes Wilhelmus John F. THURING, Marcel VIELLEVOYE
  • FUSED BICYCLIC INHIBITORS OF MENIN-MLL INTERACTION
    Publication number: 20190218230
    Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to fused bicyclic compounds, pharmaceutical composition comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, myelodysplastic syndrome (MDS) and diabetes.
    Type: Application
    Filed: September 13, 2017
    Publication date: July 18, 2019
    Applicant: Janssen Pharmaceultica nv
    Inventors: Patrick Rene ANGIBAUD, Vineet PANDE, Barbara HERKERT, Daniel Jason KROSKY, Olivier Alexis Georges QUEROLLE, Aaron Nathaniel PATRICK
  • SPIRO BICYCLIC INHIBITORS OF MENIN-MLL INTERACTION
    Publication number: 20190211036
    Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to spiro bicyclic compounds, pharmaceutical composition comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, myelodysplastic syndrome (MDS) and diabetes.
    Type: Application
    Filed: September 13, 2017
    Publication date: July 11, 2019
    Inventors: Patrick Rene ANGIBAUD, Vineet PANDE, Barbara HERKERT, Daniel Jason KROSKY, Olivier Alexis Georges QUEROLLE, Aaron Nathaniel PATRICK, Isabelle Noelle Constance PILATTE
  • Substituted Thiohydantoin Derivatives As Androgen Receptor Antagonists
    Publication number: 20180298021
    Abstract: Disclosed are compounds, compositions and methods for treating of disorders that are affected by the antagonism of one or more androgen receptor types. Such compounds are represented by Formula (I) as follows: wherein R1 and G are defined herein.
    Type: Application
    Filed: June 19, 2018
    Publication date: October 18, 2018
    Inventors: Gilles Bignan, Peter J. Connolly, Ian Hickson, Lieven Meerpoel, Vineet Pande, Zhuming Zhang, Jonathan Branch, Christian Rocaboy, Luis B. Trabalón Escolar
  • NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS
    Publication number: 20180243328
    Abstract: The present invention relates novel 6-6 bicyclic aromatic ring substituted nucleoside analogues of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as PRMT5 inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
    Type: Application
    Filed: August 25, 2016
    Publication date: August 30, 2018
    Inventors: Tongfei Wu, Dirk Brehmer, Lijs Beke, An Boeckx, Gaston Stanislas Marcella Diels, Ronaldus Arnodus Hendrika Joseph Gilissen, Edward Charles Lawson, Vineet Pande, Marcus Cornelis Bernardus Catharina Parade, Wim Bert Griet Schepens, Johannes Wilhelmus John F Thuring, Marcel Viellevoye, Weimei Sun, Lieven Meerpoel
  • Substituted thiohydantoin derivatives as androgen receptor antagonists
    Patent number: 10000502
    Abstract: Disclosed are compounds, compositions and methods for treating of disorders that are affected by the antagonism of one or more androgen receptor types. Such compounds are represented by Formula (I) as follows: wherein R1 and G are defined herein.
    Type: Grant
    Filed: January 11, 2017
    Date of Patent: June 19, 2018
    Assignee: Janssen Pharmaceutica NV
    Inventors: Gilles Bignan, Peter J Connolly, Ian Hickson, Lieven Meerpoel, Vineet Pande, Zhuming Zhang, Jonathan Branch, Christian Rocaboy, Luis B Trabalón Escolar
  • SUBSTITUTED THIOHYDANTOIN DERIVATIVES AS ANDROGEN RECEPTOR ANTAGONISTS
    Publication number: 20170233401
    Abstract: Disclosed are compounds, compositions and methods for treating of disorders that are affected by the antagonism of one or more androgen receptor types. Such compounds are represented by Formula (I) as follows: wherein R1 and G are defined herein.
    Type: Application
    Filed: January 11, 2017
    Publication date: August 17, 2017
    Inventors: Gilles Bignan, Peter J. Connolly, Ian Hickson, Lieven Meerpoel, Vineet Pande, Zhuming Zhang, Jonathan Branch, Christian Rocaboy, Luis B. Trabalón Escolar